Clinical Trials Logo

Clinical Trial Summary

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease affecting children, characterized by chronic synovitis with systemic multi-organ damage. Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA defined as disease involving more than five joints in the first 6 months of disease. This study will assess how safe and effective adalimumab (Humira®) is in treating pediatric participants with pJIA in China real-world setting. Adalimumab is an approved drug for the treatment of pJIA. Approximately 50 participants age 2 to 17 who are prescribed adalimumab for the treatment of pJIA in routine clinical practice will be enrolled at multiple sites in China. Participants will receive adalimumab per their physician's usual prescription. Individual data will be collected for 52 weeks. No additional study-related tests will be conducted during the routine physician visits. Only data which are routinely collected during a regular visit will be utilized for this study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05411211
Study type Observational
Source AbbVie
Contact ABBVIE CALL CENTER
Phone 844-663-3742
Email abbvieclinicaltrials@abbvie.com
Status Recruiting
Phase
Start date November 10, 2022
Completion date June 26, 2024

See also
  Status Clinical Trial Phase
Completed NCT02141984 - Surveillance of Humira in Korean JIA Patients N/A
Completed NCT04018599 - Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS Phase 1
Completed NCT00144625 - Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Phase 3
Active, not recruiting NCT05754710 - Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis